Frontlight ResearchEarly access
TerminatedNo phase
The FibreGum Study - Changing the Course of Obesity in Children
Key facts
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Where
- Switzerland2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 93 people enrolled
- Started
- 30 Nov 2022
- Ended
- 23 Jan 2026
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- FibreGum
- Placebo
- Record updated
- 18 February 2026
- Why it stopped
- Based on the Intention To Treat interim analysis results and the slow recruitment rate.
Who can take part
- Age
- 10 years to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Informed Consent according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (ICH/GCP) regulations prior to any study specific procedures
- Obesity as determined by a BMI ≥97th percentile using the Swiss paediatric, age- and sex-matched growth charts
- Newly referred within the last month to a tertiary weight management clinic
- Participant willing to use the study specific monitoring app on his/her own or legal representatives' smartphone
Who cannot take part
- Malignant disease on treatment or previous tumour affecting the appetite system (e.g., suprasellar, hypothalamic tumours)
- Systemic antibiotic or anti-inflammatory medication (e.g. systemic intake of glucocorticoids) over the last 7 days
- Participation in another investigation with an investigational drug within the 30 days preceding and during the present investigation
- Congenital disorder affecting the cardiovascular, hepatic or respiratory system in a relevant way (as per PI's or specialist's evaluation)
- Known eating disorder (medically diagnosed)
- Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, etc. of the participant and/or legal representative
- Antibiotic administration in the last 6 months
- Pre- or probiotic treatment in the last 6 weeks
- Any professionally supervised treatment for weight management within the last year
- Consumption of more than one nicotine product per month (e.g. cigarette, gum)
- Adolescent females: any stages of known pregnancy or lactation period
- Dependency from the sponsor or the clinical investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is thus to assess the effect of a chewing gum containing fibres on body weight, metabolism and the oral and intestinal microbiomes in a population of obese children.
The 3 groups in the trial
- PlaceboPlacebo, for comparison
Chewing gum containing maltitol powder
- InvestigationalTreatment being tested
chewing gums containing fibers
Treatment: FibreGum
- No-treatment controlNo study treatment, for comparison
No study chewing gum
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 18 February 2026